Werewolf Therapeutics, Inc.
HOWL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785530
In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Werewolf Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 38 | 36 | −2 |
| Shares | 24.0M | 24.0M | +54.5K (+0.2%) |
| Value | $62.5M | $73.3M | +$10.8M (+17.4%) |
New holders (2)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Simplex Trading, LLC | 629 | $1.00K | 0.00% |
| GHP Investment Advisors, Inc. | 80 | $209 | 0.00% |
Sold out (4)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Marshall Wace, LLP | 120,936 | $314.4K |
| Man Group plc | – | $117.3K |
| Bailard, Inc. | 18,127 | $47.1K |
| Royal Bank of Canada | 2 | $0 |